Therefore, suppressing GvHD-inducing T cell responses by reducing antigen presentation via MHC classes I and II, co-stimulatory signals such as CD80, and pro-inflammatory cytokines while promoting the expansion of GvHD-suppressing Tregs is a promising strategy to mitigate GvHD. This evidence concerns the gene CD80 and graft versus host disease.